InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
August 10, 2021 16:05 ET | Interpace Biosciences, Inc.
 ●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company’s Highest Revenue Quarter  ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
May 11, 2021 16:47 ET | Interpace Biosciences, Inc.
 ● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business  ● Q2 Revenue Expected to Exceed $11 million  ● On Track to Exceed Full Year 2021...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
May 03, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
InterpaceBiosciences_New Logo.png
Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value
April 22, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today issued the following statement. Interpace continues to make...
LOGO.jpg
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
April 05, 2021 16:05 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has...
LOGO.jpg
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
March 31, 2021 17:20 ET | Interpace Biosciences, Inc.
2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter Net Revenue of $9.6M Million Up 129% vs Prior Year; Provides Full Year 2021 Range of RevenuesOn Target to Achieve...
LOGO.jpg
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
March 17, 2021 07:30 ET | Interpace Biosciences, Inc.
Part of Company’s Site Consolidation and Cost Savings Measures Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into...
LOGO.jpg
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
February 25, 2021 16:31 ET | Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or “the Company”), today...
LOGO.jpg
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
February 24, 2021 17:54 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...
LOGO.jpg
Interpace Biosciences Announces Path Forward in Letter to Shareholders
February 16, 2021 21:21 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to...